文献速递毛发、甲与色素性疾病

一项开放标签先导研究:评估托法替尼治疗中重度斑片型斑秃、全秃和普秃的疗效

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
PubMed 文献 · J Invest Dermatol · 2018-02-13

该开放标签先导研究纳入12例中重度斑秃患者,11例完成全程治疗且不良事件轻微。初始剂量5 mg每日两次应答有限后对无应答者加量至10 mg每日两次,12例中8例达到≥50%毛发再生,3例<50%,1例无再生。基因表达谱和斑秃疾病活动指数评分与临床应答相关。

要点

  • 12例中重度斑秃患者中8例达到≥50%毛发再生,3例<50%,1例无再生。
  • 初始5 mg每日两次应答有限后,对无应答者加量至10 mg每日两次。
  • 基因表达谱和斑秃疾病活动指数评分与临床应答相关。

核心结论

  • 托法替尼治疗中重度斑秃显示显著临床应答,为使用JAK抑制剂开展更大规模临床试验提供了有力依据。

研究设计与样本

  • 开放标签先导研究,纳入12例中重度斑秃患者,其中11例完成全程治疗。

主要发现

  • 12例中8例达到≥50%毛发再生,3例<50%毛发再生,1例无再生,依据严重程度秃发工具评分。
  • 初始剂量5 mg每日两次应答有限后,对无应答者加量至10 mg每日两次。
  • 基因表达谱和斑秃疾病活动指数评分与临床应答相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of ∼2%. In AA, the immune system targets the hair follicle, resulting in clinical hair loss. The prognosis of AA is unpredictable, and currently there is no definitive treatment. Our previous whole genome expression studies identified active immune circuits in AA lesions, including common γ-chain cytokine and IFN pathways. Because these pathways are mediated through JAK kinases, we prioritized clinical exploration of small molecule JAK inhibitors. In preclinical trials in mice, tofacitinib successfully prevented AA development and reversed established disease. In our tofacitinib trial in 12 patients with moderate to severe AA, 11 patients completed a full course of treatment with minimal adverse events. Following limited response to the initial dose (5 mg b.i.d.), the dose was escalated (10 mg b.i.d.) for nonresponding subjects. Eight of 12 patients demonstrated ≥50% hair regrowth, while three patients demonstrated <50% hair regrowth, as measured by Severity in Alopecia Tool scoring. One patient demonstrated no regrowth. Gene expression profiles and Alopecia Areata Disease Activity Index scores correlated with clinical response. Our open-label studies of ruxolitinib and tofacitinib have shown dramatic clinical responses in moderate to severe AA, providing strong rationale for larger clinical trials using JAK inhibitors in AA. ClinicalTrials.gov ID NCT02299297.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Jabbari A, Sansaricq F, Cerise J, et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Invest Dermatol. 2018. PMID: 29452121. doi:10.1016/j.jid.2018.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。